Hyderabad, India, March 30, 2026 (GLOBE NEWSWIRE) – The artificial intelligence (AI) in drug discovery market is on a growth trajectory, with a valuation of USD 2.58 billion in 2025 and projections to reach USD 10.29 billion by 2031, according to a report by Mordor Intelligence. This represents a compound annual growth rate (CAGR) of 25.94% from USD 3.25 billion in 2026. The surge in market size is primarily attributed to the increasing integration of AI technologies in pharmaceutical and biotechnology research, aiming to streamline drug discovery processes.
AI systems are being harnessed to significantly reduce the timeline for drug discovery, cut development costs, and enhance the success rates of identifying viable drug candidates. The incorporation of advanced analytics, machine learning, and big data is revolutionizing traditional methodologies in drug development, transforming them into more efficient and predictive workflows. As a result, pharmaceutical companies are increasingly collaborating with technology providers to exploit AI’s capabilities in drug design, repurposing existing medications, and discovering biomarkers.
AI technologies facilitate the expedited identification of drug targets, optimization of molecular structures, and prediction of clinical outcomes, thereby enhancing the speed at which new therapies can be brought to market. This trend is further fueled by rising investments in research and development and the growing availability of large biological datasets, both of which are crucial for supporting market expansion. The role of AI in advancing precision medicine is also noteworthy, allowing for personalized drug development tailored to individual patient data.
“Current evidence indicates that AI adoption in drug discovery is progressing alongside broader digitalization trends, with measurable but evolving commercial impact,” said Soumya Goud, Senior Research Manager at Mordor Intelligence. “This assessment reflects consistently structured research processes and cross-verified inputs, providing decision-makers with a balanced, comparable view relative to other available studies.”
The geographical breakdown of the AI in drug discovery market reveals that North America holds a significant market share, bolstered by a robust presence of pharmaceutical and biotechnology firms, advanced digital infrastructure, and substantial investments in AI research. The region continues to lead in innovation and early adoption of AI-driven drug discovery platforms. Meanwhile, Europe is also well-positioned, benefiting from collaborative research initiatives and a strong emphasis on innovation in pharmaceutical research.
The Asia-Pacific region is rapidly emerging as a high-growth area, characterized by expanding biotechnology sectors and increasing investments in AI technologies. Countries such as China, India, and Japan are at the forefront of adopting digital healthcare solutions, further propelling growth in this market.
As AI technology evolves, several trends are shaping the landscape of drug discovery. The increasing use of AI for target identification and drug design is enhancing the efficiency of early-stage drug discovery. In addition, strategic partnerships between pharmaceutical firms and AI technology providers are fostering innovation and enabling the development of advanced drug discovery platforms.
The competitive outlook of the AI in drug discovery market showcases a blend of global pharmaceutical companies and specialized AI-driven technology firms dedicated to innovation and platform development. Key market participants are investing in advanced algorithms, expanding data capabilities, and forming partnerships to enhance drug discovery efficiency and maintain a competitive advantage. Notable players in the market include Recursion Pharmaceuticals.
In summary, the AI in drug discovery market is poised for substantial growth, underpinned by technological advancements and an increasing commitment from the pharmaceutical industry to leverage AI. As regulatory bodies and healthcare stakeholders increasingly recognize the efficiency gains AI brings to drug discovery, the momentum behind its adoption is expected to continue to accelerate, reshaping the future of pharmaceuticals.
See also
NSF Announces $56 Million for AI Coordination Hubs to Boost Workforce Skills Nationwide
Apple Research Reveals Entropy-Preserving Techniques to Enhance Reinforcement Learning Performance
New Research Reveals 23% of Companies Prefer Voice AI Agents by 2026
MIT Researchers Develop ‘Humble’ AI Framework to Enhance Medical Decision-Making
Google Funds $50K for UH Mānoa’s AI and Robotics Research in Agriculture and Health
